This publication summarises a symposium held on Tuesday 21st May 2024, covering the burden of respiratory syncytial virus (RSV) in older adults, and use of the Arexvy (RSVPreF3 OA) vaccine to prevent RSV-associated lower respiratory tract disease in this population. The event was chaired by Dr John Cameron, an Auckland General Practitioner, and featured presentations from Dr Hasan Bhally, Clinical Director for Infection Service at Waitemata Health, and Professor Michael Woodward, Head of Dementia Research at Austin Health in Melbourne, Australia. The symposium was organised and funded by GlaxoSmithKline (GSK).
Please login below to download this issue (PDF)